Elisa Act
ELISA/ACT Biotechnologies (Elisa Act) was a Sterling, US-based specialty diagnostics company that operated the patented Lymphocyte Response Assay (LRA) testing platform for healthcare practitioners from 1984 until its 2024 discontinuation, with its legacy now continuing through sister company PERQUE Integrative Health.
- Company typePrivate
- Founded1984
- HeadquartersSterling, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Elisa Act does
ELISA/ACT Biotechnologies (EAB), doing business as Elisa Act, was a privately held specialty diagnostics company founded in 1984 by Russell M. Jaffe, MD, PhD, CCN, NACB and headquartered in Sterling, United States. The company developed and commercialized the patented Lymphocyte Response Assay (LRA) by ELISA/ACT, an ex-vivo laboratory testing platform that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals. This testing methodology provided clinicians with diagnostic insight into immune tolerance and overload, positioning the company within the personalized and functional immunology segment of clinical diagnostics.
The company operated a business-to-business model, serving integrative health practitioners, functional medicine clinicians, and other healthcare providers seeking root-cause diagnostic insights for patients with chronic conditions. Its primary customer base comprised thousands of clinicians who integrated the LRA testing into workflows for uncovering hidden immune triggers. Pricing was not publicly disclosed, and the company maintained a lean operating structure of 1-10 employees. Beyond its core LRA testing service, the company offered a secondary Microbiome Support Protocol combining recommended diagnostic tests with targeted nutraceuticals for gut and immune health.
In 2024, after over 40 years of operation, ELISA/ACT Biotechnologies announced the discontinuation of its operations, with the LRA by ELISA/ACT tests permanently retired. The company has redirected its focus and resources to its sister company, PERQUE Integrative Health, which carries forward Dr. Jaffe's science-based legacy through nutritional solutions and clinical protocols rather than diagnostic testing services. As of the reporting date, the company's operating status is closed.
Elisa Act firmographics
Firmographics- Name
- Elisa Act
- Legal name
- ELISA/ACT Biotechnologies (EAB)
- Website
- https://elisaact.com
- Company type
- Private
- Founded year
- 1984
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Short description
- ELISA/ACT Biotechnologies (Elisa Act) was a Sterling, US-based specialty diagnostics company that operated the patented Lymphocyte Response Assay (LRA) testing platform for healthcare practitioners from 1984 until its 2024 discontinuation, with its legacy now continuing through sister company PERQUE Integrative Health.
- Ownership category
- akta.pro rank
Elisa Act industry classification
Industry- Product category
- Clinical Diagnostic Services
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Autoimmune & Allergy Diagnostics (HLAAALAK)
- akta.pro secondary industries
- Food Allergy Evaluation & Management (HLAKAAAD), Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA)
Keywords
Where Elisa Act is headquartered
LocationHeadquarters
- HQ city
- Sterling
- HQ country
- United States
- HQ region
- North America
Markets served
Elisa Act business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Technology or R&D, Personnel, Marketing or Sales
Elisa Act product offering
Product offeringCore offering
Elisa Act (ELISA/ACT Biotechnologies) provided the patented Lymphocyte Response Assay (LRA) by ELISA/ACT — an ex-vivo diagnostic test that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals. The test delivered insight into immune tolerance and overload to help clinicians identify root-cause triggers of chronic conditions. The company also offered a Microbiome Support Protocol combining Dr. Jaffe-recommended tests with targeted PERQUE nutraceuticals to address inflammation, gut restoration, and immune balance.
Product overview
Elisa Act (ELISA/ACT Biotechnologies) operated as a single-core-product company offering the LRA by ELISA/ACT testing platform for personalized immunology. This patented Lymphocyte Response Assay was the company's primary offering for detecting delayed hypersensitivity reactions. The company has announced discontinuation of operations as of the information date, with the LRA by ELISA/ACT tests not returning. A secondary offering, the Microbiome Support Protocol, provides targeted nutraceutical-based support for gut and immune health, linking to their sister company PERQUE Integrative Health for continued service delivery.
Differentiator
Problem solved
Functional benefit
Brands
- LRA by ELISA/ACT: Patented Lymphocyte Response Assay testing platform that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals.
Products and services
- LRA by ELISA/ACT Patented Lymphocyte Response Assay (LRA) ex-vivo testing that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals, providing insight into immune tolerance and overload. It is used by healthcare practitioners — particularly in integrative and functional medicine — to uncover hidden immune triggers at the root of chronic conditions.
- Microbiome Support Protocol Comprehensive protocol combining Dr. Jaffe-recommended tests and targeted PERQUE nutraceuticals, designed to assess inflammation, repair deficit, support gut restoration, and promote immune balance for patients identified through functional medicine workups.
Companies that use Elisa Act
Customer profileSegments1 record
Ideal customer profiles1 record
Elisa Act technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Elisa Act partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights3 records
Elisa Act competitors and assessment
Company assessmentDirect peers
- US Biotek Laboratories: Specialty lab offering ELISA-based food sensitivity, allergy, and environmental chemical panels via practitioner channels — a near-direct alternative to the LRA by ELISA/ACT for delayed hypersensitivity-style testing.
- Mosaic Diagnostics (formerly Great Plains Laboratory): Specialty clinical lab offering immunology, food sensitivity, and environmental reactivity panels to functional medicine providers. Comparable to ELISA/ACT in target customer (integrative clinicians) and test category (delayed hypersensitivities).
- Vibrant Wellness: Clinical lab offering food sensitivity, immune reactivity, and related panels through a practitioner-facing model. Overlaps with ELISA/ACT in addressing delayed hypersensitivities and chronic-condition root-cause workups.
- Doctor's Data: Specialty reference lab serving integrative and functional medicine practitioners with immunology, food reactivity, and related panels. Comparable in channel (clinician-direct) and category (immune/food sensitivity diagnostics).
- Genova Diagnostics: Clinical laboratory providing immune, food sensitivity, and functional medicine testing panels to healthcare practitioners. Closely overlaps ELISA/ACT in customer base (functional/integrative clinicians), testing categories (food and chemical reactivity), and CLIA-style service delivery.
- Cyrex Laboratories: Specialty clinical laboratory offering arrays of immune reactivity and food/chemical sensitivity testing (including gluten, autoimmune, and environmental antigen panels) marketed to functional and integrative medicine practitioners — directly comparable to ELISA/ACT's LRA platform.
- Cell Science Systems (ALCAT Test): Operator of the ALCAT food and chemical sensitivity test, an ex-vivo cellular assay marketed to clinicians for identifying food/chemical intolerances. Directly competes with ELISA/ACT on the same functional medicine use case of identifying hidden immune reactivity.
Broad incumbents
- Quest Diagnostics: Large national reference laboratory offering a broad menu of immunology and allergy diagnostics. Provides overlapping capability (allergen/immune testing) but is a mainstream, broad-line incumbent rather than a niche functional-medicine specialist like ELISA/ACT.
- Laboratory Corporation of America (Labcorp): Major national reference lab offering allergy and immunology panels among its broad testing menu. Overlaps categorically with ELISA/ACT but competes in mainstream clinical channels rather than the integrative/functional medicine niche.
Others
- PERQUE Integrative Health: Sister company to ELISA/ACT Biotechnologies, now carrying Dr. Jaffe's science-based legacy through nutritional solutions, clinical protocols, and the Microbiome Support Protocol. Not a direct competitor but the closest corporate/strategic entity preserving the founder's immunology work.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Elisa Act financial estimates
Financial estimateRevenue estimate
Valuation estimate
Elisa Act leadership team
Management profileNumber of profiles
Elisa Act funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Elisa Act M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Elisa Act
What does Elisa Act do?
Elisa Act (ELISA/ACT Biotechnologies) provided the patented Lymphocyte Response Assay (LRA) by ELISA/ACT — an ex-vivo diagnostic test that directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals. The test delivered insight into immune tolerance and overload to help clinicians identify root-cause triggers of chronic conditions. The company also offered a Microbiome Support Protocol combining Dr. Jaffe-recommended tests with targeted PERQUE nutraceuticals to address inflammation, gut restoration, and immune balance.
Is Elisa Act a public or private company?
Elisa Act is a private company. It is classified as founder individual operated bootstrapped and is currently closed.
When was Elisa Act founded?
Elisa Act was founded in 1984. It employs 1 to 10 people.
Where is Elisa Act based?
Elisa Act is headquartered in Sterling, United States, in the North America region.
Who are Elisa Act's main competitors?
Direct peers on record are US Biotek Laboratories, Mosaic Diagnostics (formerly Great Plains Laboratory), Vibrant Wellness, Doctor's Data, Genova Diagnostics, Cyrex Laboratories and Cell Science Systems (ALCAT Test). Broad incumbents are Quest Diagnostics and Laboratory Corporation of America (Labcorp). PERQUE Integrative Health is listed as an others.
Does Elisa Act have an API?
No public API is recorded for Elisa Act.
What industry is Elisa Act in?
Elisa Act's product category is Clinical Diagnostic Services. Its primary akta.pro industry code is HLAAALAK, Autoimmune & Allergy Diagnostics, with a secondary code of HLAKAAAD, Food Allergy Evaluation & Management. Its NAICS code is 621511 and its SIC code is 8071.